Biogen (BIIB) Inks Agreement to Add New Biosimilar Candidate

Posted byZacks Equity Research Leave a comment on Biogen (BIIB) Inks Agreement to Add New Biosimilar Candidate

Biogen (BIIB) signs an agreement with Xbrane Biopharma for exclusive global rights to the latter’s biosimilar candidate, Xcimzane, referencing UCB’s arthritis drug, Cimzia.

Leave a comment

Your email address will not be published. Required fields are marked *